Track Sun Pharmaceutical Industries Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: -1.94 %
Low
1,725.5
High
1,796.9
1 Month returns: -5.19 %
Low
1,725.5
High
1,891.5
1 Year returns: 5.57 %
Low
1,583.6
High
2,047.6
3 Year CAGR: 15.24 %
Low
1,068.3
High
2,047.6
5 Year CAGR: 15.52 %
Low
733.7
High
2,047.6
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Sun Pharmaceutical Industries Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Sun Pharmaceutical Industries Ltd. Shareholding Pattern
Quarterly breakdown of Sun Pharmaceutical Industries Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Sun Pharmaceutical Industries Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Sun Pharmaceutical Industries Ltd.?
The current share price of Sun Pharmaceutical Industries Ltd. is ₹ 1,746.40 as of 14 Oct 2026.
What is the market capitalisation of Sun Pharmaceutical Industries Ltd.?
The market capitalisation of Sun Pharmaceutical Industries Ltd. stands at ₹ 4,24,466.00 Cr.
What is the PE ratio of Sun Pharmaceutical Industries Ltd.?
The Price-to-Earnings (PE) ratio of Sun Pharmaceutical Industries Ltd. is 35.09 as of the latest trailing twelve months data.
What is the ROE and ROCE of Sun Pharmaceutical Industries Ltd.?
Sun Pharmaceutical Industries Ltd. has a Return on Equity (ROE) of 14.74% and a Return on Capital Employed (ROCE) of 16.64% as per the latest financial reports.
What is the 52-week high and low of Sun Pharmaceutical Industries Ltd.?
The 52-week high of Sun Pharmaceutical Industries Ltd. is - and the 52-week low is -.
What is the dividend yield of Sun Pharmaceutical Industries Ltd.?
The dividend yield of Sun Pharmaceutical Industries Ltd. is 0.90% based on the current market price.
What is the FII and DII holding in Sun Pharmaceutical Industries Ltd.?
Foreign Institutional Investors (FII) hold 14.54%, Domestic Institutional Investors (DII) hold 19.91% and retail/public investors hold 6.77% of Sun Pharmaceutical Industries Ltd. shares.
What sector does Sun Pharmaceutical Industries Ltd. belong to?
Sun Pharmaceutical Industries Ltd. operates in the Healthcare sector. 87.1% of analysts have a Buy or Strong Buy rating on Sun Pharmaceutical Industries Ltd. with a consensus target price of ₹ 2,180.00, implying 23.23% upside from current levels.
What is the beta of Sun Pharmaceutical Industries Ltd.?
The beta of Sun Pharmaceutical Industries Ltd. is 0.45, indicating its price volatility relative to the broader market. Over the past 1 year, Sun Pharmaceutical Industries Ltd. has delivered an absolute return of 6.94%.
What is the RSI of Sun Pharmaceutical Industries Ltd.?
The 14-day Relative Strength Index (RSI) of Sun Pharmaceutical Industries Ltd. is 35.66, placing it approaching oversold territory. An RSI above 70 is considered overbought and below 30 is considered oversold.
Stock Analysis
Fundamental analysis overview of Sun Pharmaceutical Industries Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Strong price momentum
Price Momentum score of 73.6 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
73.6 / 100
Analysts have been raising forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has increased by 0.64% in the last 3 months, indicating earnings momentum
What is Earnings upgrade (3M)?
High and stable operating margin
The company reported strong operating margin of 22.93% for 12-month ended 30 Jun 2026 and operating margin declined marginally by -101 bps from 1 year ago
What is Operating profit margin?
Moderate EPS growth and above median growth of industry
The company delivered moderate EPS growth of 14.91% for 12-month ended 30 Jun 2026 and the growth was 7.46 percentage points higher than median growth of industry
What is EPS growth (1Y)?
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.06 as on 30 Jun 2026 and Debt to Equity increased marginally by 0.03 in the last 1 year
What is Debt to Equity?
Consistently pays dividend
The company has not missed dividend payments once in the last 10 financial years
What is Dividend streak?
Company is net cash
The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet
What is Net Debt ?
Negative
Expensive and at a premium to industry median P/E
PE TTM of 35.09 indicates that the stock is expensive on a standalone basis and is at a 10.1% premium to industry median P/E
What is P/E Ratio?
Median: 31.87
Value 35.09
-0.8716.76
Low dividend yield
The company has a low dividend yield of 0.9%
What is Dividend yield?
Neutral
Moderate and stable ROE
The company reported moderate ROE of 14.74% for 12-month ended 30 Jun 2026 and ROE declined marginally by -135 bps from 1 year ago
What is ROE (FY)?
Moderate revenue growth and in line with median growth of industry
The company delivered moderate revenue growth of 11.41% for 12-month ended 30 Jun 2026 and the growth was 0.73 percentage points higher than median growth of industry
What is Sales growth (1Y)?
Median: 10.68
Value 11.41
-99.6111701.8
Company's earnings are of moderate quality
Earnings quality score of 58.2 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
58.2 / 100
No red flags found!
No significant red flags found in the stock.
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Mar 2020
Jun 2020
Sep 2020
Dec 2020
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Promoter
54.69
54.69
54.69
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
Indian Promoter
54.69
54.69
54.69
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
54.48
Foreign Promoter
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Institutions
32.37
32.81
32.83
33.03
33.29
33.47
33.80
33.99
34.46
34.61
35.63
36.01
36.12
36.23
36.44
36.59
36.54
36.51
36.62
36.59
36.66
36.75
36.78
36.93
37.04
36.70
Mutual Funds / UTI
10.94
10.52
10.71
11.13
11.93
12.03
11.72
11.80
11.63
11.84
12.22
12.46
12.91
13.16
13.07
12.93
12.21
12.78
12.11
12.24
12.21
12.63
12.41
12.09
11.96
12.84
FI/Bank/Insurance
8.54
9.38
9.52
9.67
9.65
9.91
9.95
9.14
8.31
7.74
6.53
5.69
5.23
5.27
5.16
5.09
5.12
5.00
5.00
4.79
4.95
5.15
6.04
6.66
6.93
7.07
Govt
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
FII
12.81
12.70
12.38
12.19
11.67
11.50
12.07
13.00
14.44
14.95
15.99
16.87
16.88
16.48
16.78
17.08
17.72
17.23
18.01
18.05
17.96
17.26
16.55
16.12
15.93
14.54
Other Institutions
0.08
0.21
0.23
0.04
0.04
0.04
0.05
0.06
0.08
0.09
0.89
0.99
1.10
1.31
1.43
1.51
1.49
1.50
1.48
1.51
1.53
1.71
1.78
2.07
2.22
2.26
Non-Institution
12.94
12.50
12.48
12.49
12.23
12.05
11.72
11.53
11.06
10.91
9.88
9.51
9.41
9.29
9.07
8.92
8.97
9.02
8.90
8.93
8.87
8.77
8.73
8.58
8.48
8.82
Bodies Corporate
3.63
3.51
3.40
3.31
3.27
3.22
3.19
3.02
2.94
2.90
2.31
2.31
2.28
2.25
2.15
2.14
2.09
2.09
2.10
2.10
2.08
2.07
2.05
2.03
2.02
2.05
Others (incl. Retail)
No. of shareholders
9.31
6,27,434
8.99
6,49,529
9.08
6,84,731
9.18
6,48,267
8.96
7,05,358
8.83
7,53,731
8.53
6,72,428
8.51
6,77,276
8.12
6,58,824
8.01
6,43,762
7.57
6,40,165
7.20
6,28,961
7.13
6,21,913
7.04
6,21,219
6.92
6,13,259
6.78
6,09,281
6.88
6,27,631
6.93
6,69,352
6.80
6,53,386
6.83
6,85,515
6.79
7,00,820
6.70
7,19,842
6.68
7,39,891
6.55
7,07,145
6.46
6,87,393
6.77
7,06,599
Holdings and Presence
Indices and prominent investors with a stake in this stock.
Desai Associates Partnership firm in which Ms. Meera Desai wife of Mr. Sailesh T. Desai Whole-time Director is one of the partners
Other
December-2022
Market Sale (Disposal)
2nd Dec 2022
0.01 %
₹ 1,055.00
1.00 k
₹ 10.55 lac
Sailesh T. Desai
Director
December-2022
Market Sale (Disposal)
1st Dec 2022
0.09 %
₹ 1,047.63
6.00 k
₹ 62.86 lac
Desai Associates Partnership firm in which Meera Desai wife of Sailesh T. Desai WTD is a Partner
Other
December-2022
Market Sale (Disposal)
1st Dec 2022
0.01 %
₹ 1,049.00
1.00 k
₹ 10.49 lac
Sailesh T. Desai
Director
November-2022
Market Sale (Disposal)
25th Nov 2022
0.09 %
₹ 1,030.45
10.00 k
₹ 1.03 cr
…
Company Profile
Overview of Sun Pharmaceutical Industries Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty therapies, generics and consumer healthcare products. The Companys global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among others. The Company manufactures and markets a large basket of pharmaceutical formulations across chronic and acute therapies, including generic, branded generics, specialty and complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Its portfolio spans multiple dosage forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, and others. Its portfolio also includes UNLOXCYTTM, an anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty therapies, generics and consumer healthcare products. The Companys global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among other...